The varicella vaccine market is expected to register a CAGR of 5.6% during the forecast period. Varicella vaccines contain an attenuated (weakened) live strain of the varicella-zoster (chickenpox) virus. These vaccines stimulate the immune system against the varicella-zoster virus as the infection can cause serious diseases such as herpes zoster and chickenpox. Varicella vaccines are of two types namely monovalent and combination varicella vaccines. The monovalent vaccines contain a single weakened strain of the varicella-zoster virus, however, the combination of varicella vaccines contain multiple strains of infectious agents. These vaccines are used for chickenpox, herpes zoster and mumps, measles, rubella, and varicella immunization. Absence of chickenpox immunization can lead to complications such as bacterial infections of the skin, soft tissues, bones, joints or bloodstream (sepsis), pneumonia, encephalitis, and even death.
As per the study report published in Human Vaccines & Immunotherapeutic 2019, globally annual varicella disease burden is estimated to be 140 million cases, of these 4.2 million cases have severe complications that can lead to hospitalization and death, neonates and the immunocompromised individuals particularly are at high risk.
In addition, according to the Centers for Disease Control and Prevention (CDC), each year in United States approximately 11,000 individuals get hospitalize due to chicken pox complications.
Furthermore, growing awareness regarding varicella vaccines usage, active participation of government in immunization programs and surge in the acceptance of varicella vaccines are the key driving factors in varicella vaccine market.
Key Market Trends
Monovalent Varicella Vaccine Segment is Expected to Hold a Significant Market Share in the Varicella Vaccine Market
The monovalent varicella vaccine segment holds a significant market share in varicella vaccine market and is anticipated to show a similar trend over the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children compared to combination vaccines. The monovalent vaccines contain a single strain of a single varicella live vaccines, contain a weakened strain of the varicella-zoster virus. These vaccines are used for chickenpox immunization and herpes zoster immunization. According to the Centers for Disease Control and Prevention (CDC), an estimated one million cases of shingles (Herpes Zoster) occur annually in the United States. In addition, approximately 1 out of 3 people in the United States will develop shingles (Herpes Zoster) during their lifetime. Furthermore, easy availability and high adoption of monovalent products are the key driving factors in the monovalent varicella vaccine segment.
North America is Expected to Hold a Significant Share in the Market and it is Expected to do the Same during the Forecast Period
The North American region is expected to hold a major market share of the global varicella vaccine market, due to the presence of major players involved in the commercialization and development of vaccines in this region. According to the Centers for Disease Control and Prevention (CDC) estimates, more than 3.5 million cases of varicella, 9,000 hospitalizations, and around 100 deaths are prevented by varicella vaccination each year in the United States. Furthermore, the presence of well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The varicella vaccine market is consolidated and consists of a few major players. Some of the prominent players operating in the varicella vaccine market are GlaxoSmithKline PLC, Merck & Co. Inc., GC Pharma (Green Cross Holdings), Bio-Med Pvt Ltd, Novo Medi Sciences Pvt Ltd, Sanofi, Takeda Pharmaceutical Company Limited, and Mitsubishi Tanabe Pharma Corporation.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
Methodology
LOADING...
